BeOne Medicines AG (FRA:49BA)
Germany · Delayed Price · Currency is EUR 296.00
+4.00 (1.37%)
At close: Nov 28, 2025
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 1.41B CNY in the quarter ending September 30, 2025, with 41.00% growth. This brings the company's revenue in the last twelve months to 4.97B, up 49.92% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of 3.81B with 54.96% growth.
Revenue (ttm)
4.97B CNY
Revenue Growth
+49.92%
P/S Ratio
7.63
Revenue / Employee
452.06K CNY
Employees
11,000
Market Cap
32.50B EUR
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
BeOne Medicines AG News
- 25 days ago - BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M - Seeking Alpha
- 26 days ago - BeiGene Q3 2025 Earnings Preview - Seeking Alpha
- 7 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 8 months ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire